Pharmacogenetics of GABAergic mechanisms of benefit and harm in epilepsy: : A prospective cohort study to determine the enviromental and genetic factors associated with response to clobazam. - Pharmacogenetics:clobazam

liverpool university0 个研究点目标入组 400 人开始时间: 2005年2月15日最近更新: 2019年11月25日

适应症

试验速览

暂无简介。

•1. Continued seizures despite current treatment with between 1 and 3 conventional antiepileptic drugs (carbamazepine, valproate, lamotrigine, phenytoin, topiramate, levetiracetam, gabapentin). Patients who may have been treated previously with AEDs not in this list will also be included.
•2. Patients have been on their existing combination of AEDs for at least 3 months.
•3. Addition of clobazam to existing AED regime or switch of one of current AEDs for clobazam is clinically indicated.
•4. Any epilepsy syndrome (generalized, localization-related, unclassified).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

发起方

liverpool university